Patients come in having already done the research. They've seen the before-and-after posts. They know tirzepatide by its brand name, Mounjaro. They know it works better than Ozempic for weight loss. Some have already looked up the price at their nearest pharmacy. They sit down ready to ask for a prescription.
I don't say no. Tirzepatide is a genuinely effective medication for obesity and type 2 diabetes, and I prescribe it. But before I write anything, there is a conversation I have with every single patient — a conversation that most prescribers skip because it takes time, because it requires understanding both the pharmacology and the nutrition, and because it complicates what patients want to be a simple transaction.
That conversation is what this article is about.
What tirzepatide actually does — and why that matters for what comes next
Tirzepatide works on two receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is why it produces greater weight loss than semaglutide, which targets GLP-1 alone. In clinical trials, patients on tirzepatide lost between 15 and 22 percent of body weight, numbers that are genuinely impressive by the standards of any obesity treatment.
The mechanism is essentially this: the medication slows gastric emptying, reduces appetite signaling in the brain, improves insulin secretion, and decreases glucagon. Patients eat less. Significantly less. For many, the change is dramatic — the constant background noise of hunger that has driven their eating for years simply quiets.
This is the part patients are excited about, and rightly so. But it is also the part that sets up the conversation we need to have.
The muscle problem — and why Filipinos are particularly at risk
When you eat significantly less, your body loses weight. What that weight is made of depends entirely on what you eat and whether you are doing resistance exercise. In the absence of adequate protein intake and strength training, a substantial portion of what you lose will be skeletal muscle, not fat. This is called sarcopenic obesity, and it is a documented risk with rapid weight loss from any cause, including GLP-1 medications.
In the clinical trials for tirzepatide, approximately 40 percent of weight lost was lean mass in patients who were not following a structured nutrition and exercise protocol. You can lose twenty pounds on Mounjaro and end up weaker, with worse metabolic health, than when you started — if you do not address what you are eating while the medication suppresses your appetite.
This risk is higher in Filipino patients for a specific reason. The traditional Filipino diet is relatively low in protein compared to many Western diets. Rice, bread, and other refined carbohydrates make up a large proportion of most meals. Protein sources — fish, chicken, pork, eggs — are often eaten in smaller quantities alongside the main starch. When appetite is suppressed and total food intake drops significantly, protein is frequently the first thing that gets cut, because patients instinctively reach for smaller portions of carbohydrates rather than maintaining their protein intake.
Before I prescribe tirzepatide, I calculate a protein target for every patient. On the medication, I require a minimum of 1.2 grams of protein per kilogram of ideal body weight per day — and I explain exactly what that looks like in terms of Filipino food. That means itlog in the morning, isda or manok at lunch, and another protein source at dinner, in portions that are maintained even as the rest of the meal shrinks.
What happens when you stop — the conversation patients don't want to have
Tirzepatide is not a short-term intervention. It works for as long as you take it. When patients stop, appetite returns — in most cases, fully. The physiological hunger that the medication suppressed comes back, and without the behavioral habits and nutritional understanding built during the treatment period, weight regains.
This is not a criticism of the medication. It is a biological fact, and it is true of essentially every pharmacological obesity treatment. The question is what patients do with that information. There are two reasonable responses. The first is to accept that this may be a long-term or permanent medication, the same way a patient with hypertension takes antihypertensives indefinitely. The second is to use the window of reduced appetite to build genuine dietary habits that can be maintained after the medication is stopped or tapered.
Most patients who come in asking for Mounjaro have not thought about either of these options. They think of it the way they think of an antibiotic — a course of treatment, then done. I spend time on this part of the conversation because a patient who understands the rebound dynamic will approach the medication differently. They will use the appetite suppression to practice portion control, to learn what protein-adequate meals feel like, to build a dietary structure that persists beyond the prescription.
Filipino food on tirzepatide: what changes and what doesn't
Nausea is the most common side effect of tirzepatide, particularly during the dose escalation phase. It is manageable for most patients, but it is made significantly worse by high-fat meals. This matters for Filipino patients because several beloved dishes — lechon, crispy pata, bagnet, kare-kare with a generous layer of fat — are high in fat and will reliably worsen nausea during the early weeks of treatment. I tell patients directly: the first month is not the time for a fiesta table.
What I recommend instead during the early phase is a temporary shift toward lighter Filipino preparations: sinigang, tinola, paksiw, pinakbet, fish and vegetable dishes, soups with the fat skimmed. Not because these are the only healthy options, but because they are gentler on a stomach that is adapting to a new medication.
Beyond nausea management, tirzepatide changes the nutritional calculus in an important way: when total food volume drops, the quality of what remains matters more. A patient eating 30 percent less food than before cannot afford to fill that reduced intake with white rice and leave protein behind. The medication compresses the margin. Nutrient density becomes non-negotiable.
On cost and duration: the honest conversation about ₱
Tirzepatide is expensive in the Philippines. At current pricing, a single auto-injector pen runs between ₱15,000 and ₱25,000 depending on the dose and the pharmacy, and patients require one per week. At maintenance dose, that is ₱60,000 to ₱100,000 per month — a significant financial commitment that most Filipino families cannot sustain indefinitely without planning.
This is a conversation I have explicitly, not because I want to discourage patients from a medication that works, but because a patient who runs out of medication mid-treatment without a plan — and then abandons it — is worse off than a patient who understood the cost from the start and made a deliberate decision about how long they intended to continue. Starting tirzepatide without a budget plan is not a neutral choice. It often ends in abrupt discontinuation, which is the most common reason for the rebound weight gain I mentioned earlier.
I ask patients how long they can realistically commit to the cost. We build a treatment plan around the honest answer — whether that is six months of aggressive loss followed by a structured transition, or indefinite maintenance for a patient with severe obesity-related comorbidities who needs it long-term.
Why the prescriber needs to be both MD and RND
Most internists and endocrinologists who prescribe tirzepatide are not nutritionist-dietitians. They understand the pharmacology well. What they may not have the training to provide is the nutritional co-management that makes the medication work the way it is supposed to — the protein targets, the Filipino food adaptations, the meal structure, the composition monitoring that distinguishes fat loss from muscle loss.
Conversely, a registered nutritionist-dietitian can manage the dietary side but cannot write the prescription.
Patients on tirzepatide ideally need both. In most cases, they see the prescribing physician separately from a dietitian, if they see a dietitian at all. The coordination is imperfect, the messaging is sometimes inconsistent, and the nutrition side — which is where most of the long-term outcome is determined — is often deprioritized.
The reason I have the conversation I described in this article is that I can. I write the prescription and the medical nutrition plan in the same room, grounded in the same clinical reasoning. The medication and the nutrition are not two separate treatment tracks. They are one plan.
If you are considering tirzepatide, or you have already been prescribed it and feel like you are missing guidance on the nutrition side, that gap is real — and it is worth addressing before the medication does the work without the foundation to support what comes after.
